
Recent research into the causal human biology of neurodegenerative conditions has suggested that turning down the ISR may help slow neurodegeneration and improve cognitive function.1
Researchers are targeting eIF2B as a potential way to help overcome long-term activation of the ISR and its harmful effects.
Preclinical research has shown that activating eIF2B may preserve neuronal structure and synaptic function by restoring normal protein homeostasis. This could result in improved long-term memory and address other neurological symptoms such as cognitive decline across a range of diseases, including Alzheimer’s disease.4-7